ReviewNeurosurgical review2022
The role of systemic inflammatory cells in meningiomas.
Review in Neurosurgical review, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 24 citations in OpenAlex.
- Deficiency of SMARCB1 drives an immunosuppressive microenvironment in meningioma.Acta neuropathologica communications · 2026Article
- Epileptogenesis in meningioma: Theories, putative biomarkers, and postoperative risk.Epilepsia · 2025Review
- Tumour-associated macrophage infiltration differs in meningioma genotypes, and is important in tumour dynamics.Journal of experimental & clinical cancer research : CR · 2025Article
- Systemic inflammation versus clinical demographics: patient age surpasses the platelet-to-lymphocyte ratio in differentiating secondary trigeminal neuralgia.Frontiers in aging neuroscience · 2025Article
- Flow Cytometry Analyses of Meningioma Immune Cell Composition Using a Short, Optimized Digestion Protocol.Cancers · 2024Article
- MRI features and tumor-infiltrating CD8 + T cells-based nomogram for predicting meningioma recurrence risk.Cancer imaging : the official publication of the International Cancer Imaging Society · 2024Article
- Mast cells in meningiomas.European journal of histochemistry : EJH · 2024Article
- Multi-parametric MRI-based machine learning model for prediction of WHO grading in patients with meningiomas.European radiology · 2024Article
- Next-generation PET/CT imaging in meningioma-first clinical experiences using the novel SSTR-targeting peptide [European journal of nuclear medicine and molecular imaging · 2023Article
- Proteomic Analysis on Sequential Samples of Cystic Fluid Obtained from Human Brain Tumors.Cancers · 2023Article
- Novel Human Meningioma Organoids Recapitulate the Aggressiveness of the Initiating Cell Subpopulations Identified by ScRNA-Seq.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Gene expression analysis during progression of malignant meningioma compared to benign meningioma.Journal of neurosurgery · 2023Article
- Liquid biopsy evaluation of circulating tumor DNA, miRNAs, and cytokines in meningioma patients.Frontiers in neurology · 2023Article
- Angiomatous meningioma associated with rapidly aggravated peritumoral leptomeningitis: A case report.Surgical neurology international · 2023Article
- M2-Macrophage-Derived Exosomes Promote Meningioma Progression through TGF-Journal of immunology research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this review is to describe the inflammatory systemic cell infiltrate and its role in pathophysiology and prognostic implications of meningiomas. Articles from PubMed describing inflammation and immune cells in meningioma were systematically selected and reviewed. Infiltrating inflammatory cells are common in meningiomas and correlate with tumor behavior and peritumoral edema. The immune cell infiltrate mainly comprised macrophages, CD4 + T cells of the Th1 and Th2 subtype, CD8 + cytotoxic T cells, mast cells, and to a lesser degree B cells. The polarization of macrophages to M1 or M2 states, as well as the differentiation of T-helper cells to Th1 or Th2 subsets, is of prognostic value, but whether or not the presence of macrophages is associated with the degree of malignancy of the tumor is controversial. The best documented immunosuppressive and tumor-promoting mechanism is the expression of programmed cell death protein 1 (PD-1/PD-1L) which is found on both tumor cells and tumor-infiltrating immune cells. The immune cell infiltration varies between different meningiomas. It contributes to a microenvironment with potential contradictory effects on tumor growth and edema. The immune mechanisms are potential therapeutic targets provided that their effects can be comprehensively understood.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.